Literature DB >> 22465408

Stromal fibroblast-bone marrow-derived cell interactions: implications for myofibroblast development in the cornea.

V Singh1, V Agrawal, M R Santhiago, S E Wilson.   

Abstract

The purpose of this study was to test the hypothesis that mouse corneal stromal fibroblast and bone marrow-derived cell interactions augment corneal myofibroblast generation and, if so, to study whether such interactions are mediated by paracrine or juxtacrine mechanisms. Mouse bone marrow-derived cells and mouse corneal stromal fibroblasts were obtained from both mice with green fluorescent protein (GFP) expressed in all cells and normal GFP- BL6 control mice. To study the interactions of the different cell types, GFP+ cells of one type were co-cultured with GFP- cells of the other type in Primaria plates (to monitor juxtacrine signaling) or Transwell System plates (to monitor paracrine effects mediated by soluble mediators). Both cell types were cultured at a cell density of 1 × 10(5) cells per ml. The percentage of alpha smooth muscle actin+ myofibroblasts was significantly higher (ANOVA, p<0.001) when bone marrow-derived cells and mouse corneal stromal fibroblasts were co-cultured compared to when bone marrow-derived cells and mouse corneal stromal fibroblasts were cultured alone (control). The in vitro studies using GFP+ corneal fibroblasts or GFP+ bone marrow-derived cells demonstrated conclusively that both cells types could transform into myofibroblasts. However, the percentage of alpha smooth muscle actinassds+ myofibroblasts generated from either cell type precursor was higher when both cells were co-cultured together (juxtacrine) as compared to when bone marrow-derived cells and mouse corneal stromal fibroblasts were co-culture in different compartments of Transwell System (paracrine). Thus, more alpha smooth muscle actin+ GFP+ myofibroblasts were generated from GFP+ corneal stromal fibroblasts when GFP- bone marrow-derived cells were present and more alpha smooth muscle actin+ GFP+ myofibroblasts were generated from GFP+ bone marrow-derived cells when GFP- corneal stromal fibroblasts were present. Polyclonal anti-human latency associated peptide (LAP) (transforming growth factor-β1) neutralizing antibody (a-LAP) and/or transforming growth factor-β type I receptor kinase inhibitor (LY-364947) inhibited the generation of alpha smooth muscle actin+ myofibroblasts from either precursor cell in Transwell System co-culture experiments. These data suggest that TGFβ is a paracrine modulator that regulates the generation of myofibroblasts from either corneal fibroblasts or bone marrow-derived cell precursors.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465408      PMCID: PMC3340470          DOI: 10.1016/j.exer.2012.03.006

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.770


  39 in total

1.  IL-6 modulates alpha-smooth muscle actin expression in dermal fibroblasts from IL-6-deficient mice.

Authors:  Randle M Gallucci; Eric G Lee; James J Tomasek
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

Review 2.  The keratocyte: corneal stromal cell with variable repair phenotypes.

Authors:  Judith A West-Mays; Dhruva J Dwivedi
Journal:  Int J Biochem Cell Biol       Date:  2006-04-03       Impact factor: 5.085

Review 3.  Hepatic myofibroblasts: a heterogeneous population of multifunctional cells in liver fibrogenesis.

Authors:  Erica Novo; Lorenzo Valfrè di Bonzo; Stefania Cannito; Sebastiano Colombatto; Maurizio Parola
Journal:  Int J Biochem Cell Biol       Date:  2009-03-31       Impact factor: 5.085

4.  Inhibition of myofibroblast apoptosis by transforming growth factor beta(1).

Authors:  H Y Zhang; S H Phan
Journal:  Am J Respir Cell Mol Biol       Date:  1999-12       Impact factor: 6.914

Review 5.  Transforming growth factor beta signal transduction: a potential target for maintenance/restoration of transparency of the cornea.

Authors:  Shizuya Saika; Osamu Yamanaka; Takayoshi Sumioka; Yuka Okada; Takeshi Miyamoto; Kumi Shirai; Ai Kitano; Sai-ichi Tanaka
Journal:  Eye Contact Lens       Date:  2010-09       Impact factor: 2.018

6.  Corneal myofibroblast generation from bone marrow-derived cells.

Authors:  Flavia L Barbosa; Shyam S Chaurasia; Alicia Cutler; Kewal Asosingh; Harmet Kaur; Fabricio W de Medeiros; Vandana Agrawal; Steven E Wilson
Journal:  Exp Eye Res       Date:  2010-04-24       Impact factor: 3.467

7.  Bone marrow-derived progenitor cells in pulmonary fibrosis.

Authors:  Naozumi Hashimoto; Hong Jin; Tianju Liu; Stephen W Chensue; Sem H Phan
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

8.  ClC-3 is required for LPA-activated Cl- current activity and fibroblast-to-myofibroblast differentiation.

Authors:  Zhaohong Yin; Yiai Tong; Haiqing Zhu; Mitchell A Watsky
Journal:  Am J Physiol Cell Physiol       Date:  2007-12-12       Impact factor: 4.249

Review 9.  Smad3 as a mediator of the fibrotic response.

Authors:  Kathleen C Flanders
Journal:  Int J Exp Pathol       Date:  2004-04       Impact factor: 1.925

10.  The cellular basis of corneal transparency: evidence for 'corneal crystallins'.

Authors:  J V Jester; T Moller-Pedersen; J Huang; C M Sax; W T Kays; H D Cavangh; W M Petroll; J Piatigorsky
Journal:  J Cell Sci       Date:  1999-03       Impact factor: 5.285

View more
  21 in total

Review 1.  Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis.

Authors:  Daisy Y Shu; Frank J Lovicu
Journal:  Prog Retin Eye Res       Date:  2017-08-12       Impact factor: 21.198

2.  Lipoxin A₄ inhibits platelet-activating factor inflammatory response and stimulates corneal wound healing of injuries that compromise the stroma.

Authors:  Azucena Kakazu; Jiucheng He; Sachidananda Kenchegowda; Haydee E P Bazan
Journal:  Exp Eye Res       Date:  2012-07-22       Impact factor: 3.467

3.  Mouse strain variation in SMA(+) myofibroblast development after corneal injury.

Authors:  Vivek Singh; Andre A M Torricelli; Neema Nayeb-Hashemi; Vandana Agrawal; Steven E Wilson
Journal:  Exp Eye Res       Date:  2013-06-18       Impact factor: 3.467

Review 4.  The corneal epithelial basement membrane: structure, function, and disease.

Authors:  André A M Torricelli; Vivek Singh; Marcony R Santhiago; Steven E Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

Review 5.  Corneal myofibroblast biology and pathobiology: generation, persistence, and transparency.

Authors:  Steven E Wilson
Journal:  Exp Eye Res       Date:  2012-04-20       Impact factor: 3.467

6.  TGFβ and PDGF-B signaling blockade inhibits myofibroblast development from both bone marrow-derived and keratocyte-derived precursor cells in vivo.

Authors:  Vivek Singh; Ritika Jaini; André A M Torricelli; Marcony R Santhiago; Nirbhai Singh; Bala K Ambati; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-02-26       Impact factor: 3.467

7.  Transforming growth factor β and platelet-derived growth factor modulation of myofibroblast development from corneal fibroblasts in vitro.

Authors:  Vivek Singh; Flavia L Barbosa; Andre A M Torricelli; Marcony R Santhiago; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-01-12       Impact factor: 3.467

8.  Transmission electron microscopy analysis of epithelial basement membrane repair in rabbit corneas with haze.

Authors:  Andre A M Torricelli; Vivek Singh; Vandana Agrawal; Marcony R Santhiago; Steven E Wilson
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-06-10       Impact factor: 4.799

Review 9.  Cellular and extracellular matrix modulation of corneal stromal opacity.

Authors:  Andre A M Torricelli; Steven E Wilson
Journal:  Exp Eye Res       Date:  2014-10-01       Impact factor: 3.467

10.  A method to generate enhanced GFP+ chimeric mice to study the role of bone marrow-derived cells in the eye.

Authors:  Vivek Singh; Ritika Jaini; André A M Torricelli; Vincent K Tuohy; Steven E Wilson
Journal:  Exp Eye Res       Date:  2013-10-17       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.